<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628848</url>
  </required_header>
  <id_info>
    <org_study_id>243-05-001</org_study_id>
    <secondary_id>JapicCTI-060287</secondary_id>
    <nct_id>NCT01628848</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients</brief_title>
  <official_title>A Placebo-controlled Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate efficacy and safety of SPM 962 in
      advanced Parkinson's Disease (PD) patients in a multi-center, placebo-controlled study
      following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg
      (12 weeks of dose titration/maintenance period). Recommended maintenance dose range is also
      to be investigated with distribution of the maintenance dose and accumulated response rate of
      efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score</measure>
    <time_frame>baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing.
UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part 2 Sum Score (Average Score of on State and Off State)</measure>
    <time_frame>baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 12 weeks after dosing.
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average score of on state and off state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Off Time</measure>
    <time_frame>baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in off time at 12 weeks after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Rate in UPDRS Part 3 Sum Score</measure>
    <time_frame>Baseline, 12 weeks after dosing</time_frame>
    <description>Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score at 12 weeks after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part 1 Sum Score</measure>
    <time_frame>Baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in UPDRS Part 1 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Rate in Off Time</measure>
    <time_frame>Baseline, 12 weeks after dosing.</time_frame>
    <description>Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 12 weeks after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part 2 Sum Score (on State)</measure>
    <time_frame>Baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part 2 Sum Score (Off State)</measure>
    <time_frame>Baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS Part 4 Sum Score</measure>
    <time_frame>Baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in UPDRS Part 4 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score</measure>
    <time_frame>Baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average score of on state and off state), and UPDRS Part 3 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.</measure>
    <time_frame>Baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average score of on state and off state), UPDRS Part 3 sum score, and UPDRS Part 4 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Modified Hoehn &amp; Yahr Severity of Illness</measure>
    <time_frame>Baseline, 12 weeks after dosing</time_frame>
    <description>Mean change (LOCF) from baseline in the Modified Hoehn &amp; Yahr Severity of Illness at 12 weeks after dosing.
The Modified Hoehn &amp; Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>SPM 962</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPM 962 transdermal patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo transdermal patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPM 962</intervention_name>
    <description>SPM 962 transdermal patch once a daily up to 36.0 mg/day</description>
    <arm_group_label>SPM 962</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo transdermal patch</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject diagnosed as having Parkinson's disease in accordance with &quot;Diagnostic
             Criteria established by the Research Committee of MHLW-specified Intractable
             Neurodegenerative Diseases (1995)&quot;.

          -  Subject is 30 and more and less than 80 years of age at the time of informed consent.

          -  Hoehn &amp; Yahr stage 2-4 (on time).

          -  Total UPDRS Part 3 score is over 10 at screening test (on time).

          -  Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen
             for at least 28 days prior to the initial treatment of SPM 962.

          -  Subject has any of the following problematic symptoms; 1) Wearing off phenomenon 2) On
             and off phenomenon 3) Delayed-on and/or No-on phenomenon 4) Not well controlled with
             L-dopa due to adverse effect 5) Weakening of L-dopa efficacy.

        Exclusion Criteria:

          -  Subject has previously participated in a trial with SPM 962.

          -  Subject is on other dopamine agonist treatment within 28 days prior to the initial
             treatment.

          -  Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation,
             delirium, abnormal behavior at screening test or baseline.

          -  Subject has orthostatic hypotension.

          -  Subject has a history of epilepsy, convulsion and other.

          -  Subject has a complication of serious cardiac disorder or has the history.

          -  Subject has arrhythmia and treated with class 1a antiarrhythmic drugs (e.g. quinidine,
             procainamide etc.) or class 3 antiarrhythmic drugs (e.g. amiodarone, sotalol etc.).

          -  At screening and baseline, subject develops serious ECG abnormality. Subjects has
             QTc-interval &gt;450 msec twice at screening. Subject has a the average QTc-interval from
             two ECGs &gt;450 msec in males and &gt;470 msec in females at baseline.

          -  Subject has congenital long QT syndrome.

          -  Subject has hypokalaemia.

          -  Subject has a total bilirubin &gt;= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5
             times of the upper limit of the reference range (or &gt;= 100 IU/L) at screening test.

          -  Subject has BUN &gt;= 25 mg/dL or serum creatinine &gt;= 2.0 mg/dl at screening test.

          -  Subject has a history of allergic reaction to topical agents such as transdermal
             patch.

          -  Subject is pregnant or nursing or woman who plans pregnancy during the trial.

          -  Subject is receiving therapy with prohibited drug specified in the study protocol.

          -  Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal
             tissue transplant.

          -  Subject has dementia.

          -  Subject is unable to give consent.

          -  Subject is participating in another trial of an investigational drug or done so within
             24 weeks prior to the initial treatment.

          -  Investigator judges that subject is inappropriate as a study subject with other
             reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoji Imaoka, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2012</study_first_posted>
  <results_first_submitted>February 3, 2014</results_first_submitted>
  <results_first_submitted_qc>February 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 19, 2014</results_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPM 962</keyword>
  <keyword>rotigotine</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>concomitant use of L-dopa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SPM 962</title>
          <description>SPM 962 transdermal patch</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo transdermal patch</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Excluded 1 sebject of each arm by vaiolation of protocol</population>
      <group_list>
        <group group_id="B1">
          <title>SPM 962</title>
          <description>SPM 962 transdermal patch</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo transdermal patch</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.0" spread="6.8"/>
                    <measurement group_id="B2" value="66.8" spread="8.3"/>
                    <measurement group_id="B3" value="66.9" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score</title>
        <description>Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing.
UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
        <time_frame>baseline, 12 weeks after dosing</time_frame>
        <population>Full analysis set (FAS), last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score</title>
          <description>Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing.
UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
          <population>Full analysis set (FAS), last observation carried forward (LOCF)</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="9.0"/>
                    <measurement group_id="O2" value="-4.4" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS Part 2 Sum Score (Average Score of on State and Off State)</title>
        <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 12 weeks after dosing.
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average score of on state and off state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
        <time_frame>baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS Part 2 Sum Score (Average Score of on State and Off State)</title>
          <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 12 weeks after dosing.
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average score of on state and off state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.6"/>
                    <measurement group_id="O2" value="-1.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Off Time</title>
        <description>Mean change (LOCF) from baseline in off time at 12 weeks after dosing.</description>
        <time_frame>baseline, 12 weeks after dosing</time_frame>
        <population>FAS subjects with measurable off time data at baseline, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>Off Time</title>
          <description>Mean change (LOCF) from baseline in off time at 12 weeks after dosing.</description>
          <population>FAS subjects with measurable off time data at baseline, LOCF</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="3.1"/>
                    <measurement group_id="O2" value="-0.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effective Rate in UPDRS Part 3 Sum Score</title>
        <description>Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score at 12 weeks after dosing.</description>
        <time_frame>Baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Rate in UPDRS Part 3 Sum Score</title>
          <description>Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score at 12 weeks after dosing.</description>
          <population>FAS, LOCF</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with ≥20% decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" lower_limit="63.9" upper_limit="82.6"/>
                    <measurement group_id="O2" value="43.0" lower_limit="32.6" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with ≥30% decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="53.8" upper_limit="74.1"/>
                    <measurement group_id="O2" value="29.1" lower_limit="19.5" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS Part 1 Sum Score</title>
        <description>Mean change (LOCF) from baseline in UPDRS Part 1 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
        <time_frame>Baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS Part 1 Sum Score</title>
          <description>Mean change (LOCF) from baseline in UPDRS Part 1 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="1.34"/>
                    <measurement group_id="O2" value="-0.12" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effective Rate in Off Time</title>
        <description>Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 12 weeks after dosing.</description>
        <time_frame>Baseline, 12 weeks after dosing.</time_frame>
        <population>FAS subjects with measurable off time data at baseline, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Rate in Off Time</title>
          <description>Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 12 weeks after dosing.</description>
          <population>FAS subjects with measurable off time data at baseline, LOCF</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with ≥20% decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" lower_limit="50.1" upper_limit="75.8"/>
                    <measurement group_id="O2" value="46.4" lower_limit="33.4" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with ≥30% decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" lower_limit="38.5" upper_limit="65.2"/>
                    <measurement group_id="O2" value="37.5" lower_limit="24.8" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS Part 2 Sum Score (on State)</title>
        <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
        <time_frame>Baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS Part 2 Sum Score (on State)</title>
          <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="3.7"/>
                    <measurement group_id="O2" value="-1.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS Part 2 Sum Score (Off State)</title>
        <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
        <time_frame>Baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS Part 2 Sum Score (Off State)</title>
          <description>Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="4.5"/>
                    <measurement group_id="O2" value="-1.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS Part 4 Sum Score</title>
        <description>Mean change (LOCF) from baseline in UPDRS Part 4 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
        <time_frame>Baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS Part 4 Sum Score</title>
          <description>Mean change (LOCF) from baseline in UPDRS Part 4 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="1.73"/>
                    <measurement group_id="O2" value="-0.22" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score</title>
        <description>Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average score of on state and off state), and UPDRS Part 3 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
        <time_frame>Baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score</title>
          <description>Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average score of on state and off state), and UPDRS Part 3 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="11.4"/>
                    <measurement group_id="O2" value="-6.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.</title>
        <description>Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average score of on state and off state), UPDRS Part 3 sum score, and UPDRS Part 4 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
        <time_frame>Baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.</title>
          <description>Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average score of on state and off state), UPDRS Part 3 sum score, and UPDRS Part 4 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.6" spread="11.9"/>
                    <measurement group_id="O2" value="-6.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Modified Hoehn &amp; Yahr Severity of Illness</title>
        <description>Mean change (LOCF) from baseline in the Modified Hoehn &amp; Yahr Severity of Illness at 12 weeks after dosing.
The Modified Hoehn &amp; Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.</description>
        <time_frame>Baseline, 12 weeks after dosing</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPM 962</title>
            <description>SPM 962 transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo transdermal patch</description>
          </group>
        </group_list>
        <measure>
          <title>The Modified Hoehn &amp; Yahr Severity of Illness</title>
          <description>Mean change (LOCF) from baseline in the Modified Hoehn &amp; Yahr Severity of Illness at 12 weeks after dosing.
The Modified Hoehn &amp; Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.</description>
          <population>FAS, LOCF</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not changed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SPM 962</title>
          <description>SPM 962 transdermal patch</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo transdermal patch</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)J</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia Inguinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Consciousness Loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Neuroleptic Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hallucination, Auditory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (10.1)J</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="87"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Reaction</sub_title>
                <counts group_id="E1" events="46" subjects_affected="44" subjects_at_risk="87"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Feeling Abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hallucination Visual</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research and Development</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ltd.</organization>
      <phone>+81-3-6131-7366</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

